Givlaari
E446846
Givlaari is an RNA interference-based therapy used to treat acute hepatic porphyria by reducing the production of toxic heme intermediates in the liver.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Givlaari canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T4492414 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Givlaari Context triple: [Alnylam Pharmaceuticals, develops, Givlaari]
-
A.
Vitlycke
Vitlycke is a renowned Bronze Age rock carving site in Tanum, Sweden, noted for its extensive petroglyphs and archaeological significance.
-
B.
Freirina
Freirina is a small town and commune in northern Chile known for its agricultural activity and historic architecture within the Atacama Region.
-
C.
Novilara
Novilara is an archaeological site and locality in the Marche region of Italy, known for its ancient Picene culture remains and notable funerary stelae.
-
D.
Overhalla
Overhalla is a rural municipality in Trøndelag county, Norway, known for its agriculture, forestry, and proximity to the town of Namsos.
-
E.
Sangschaw
Sangschaw is a notable early poetry collection by Scottish modernist poet Hugh MacDiarmid, written largely in Scots and central to the Scottish literary renaissance.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Givlaari Target entity description: Givlaari is an RNA interference-based therapy used to treat acute hepatic porphyria by reducing the production of toxic heme intermediates in the liver.
-
A.
Vitlycke
Vitlycke is a renowned Bronze Age rock carving site in Tanum, Sweden, noted for its extensive petroglyphs and archaeological significance.
-
B.
Freirina
Freirina is a small town and commune in northern Chile known for its agricultural activity and historic architecture within the Atacama Region.
-
C.
Novilara
Novilara is an archaeological site and locality in the Marche region of Italy, known for its ancient Picene culture remains and notable funerary stelae.
-
D.
Overhalla
Overhalla is a rural municipality in Trøndelag county, Norway, known for its agriculture, forestry, and proximity to the town of Namsos.
-
E.
Sangschaw
Sangschaw is a notable early poetry collection by Scottish modernist poet Hugh MacDiarmid, written largely in Scots and central to the Scottish literary renaissance.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
RNA interference-based therapy
ⓘ
drug ⓘ small interfering RNA therapeutic ⓘ |
| hasAdverseEffect |
anaphylaxis
ⓘ
elevated liver enzymes ⓘ fatigue ⓘ injection site reactions ⓘ nausea ⓘ renal function impairment ⓘ |
| hasApprovalYear | 2019 ⓘ |
| hasATCCode | B06AX06 ⓘ |
| hasBlackBoxWarning | risk of anaphylactic reaction ⓘ |
| hasConjugate | N-acetylgalactosamine (GalNAc) ⓘ |
| hasDeveloper | Alnylam Pharmaceuticals ⓘ |
| hasDosageForm | solution for injection ⓘ |
| hasEffect |
reduces accumulation of toxic heme intermediates
ⓘ
reduces hepatic ALAS1 expression ⓘ reduces need for hemin treatment ⓘ reduces production of aminolevulinic acid ⓘ reduces production of porphobilinogen ⓘ reduces rate of porphyria attacks ⓘ |
| hasFrequencyOfAdministration | once monthly ⓘ |
| hasGenericName |
givosiran
ⓘ
linked to:
GIVLAARI (givosiran)
|
| hasIndication |
ALA dehydratase-deficiency porphyria
ⓘ
acute hepatic porphyria ⓘ acute intermittent porphyria ⓘ hereditary coproporphyria ⓘ variegate porphyria ⓘ |
| hasMechanismOfAction |
RNA interference
ⓘ
inhibition of ALAS1 mRNA in hepatocytes ⓘ |
| hasMolecularTarget |
ALAS1 mRNA
ⓘ
linked to:
RNA
aminolevulinate synthase 1 ⓘ |
| hasPharmacologicalClass |
gene silencing agent
ⓘ
siRNA conjugate ⓘ |
| hasPregnancyCategory | not recommended unless clearly needed ⓘ |
| hasRegulatoryApproval |
EMA
ⓘ
FDA ⓘ
linked to:
Food and Drug Administration
|
| hasRouteOfAdministration | subcutaneous injection ⓘ |
| hasTargetCellType | hepatocyte ⓘ |
| hasTherapeuticArea |
hematology
ⓘ
hepatology ⓘ metabolic disorders ⓘ rare diseases ⓘ |
| isAdministeredBy | healthcare professional ⓘ |
| requiresMonitoring |
homocysteine levels
ⓘ
liver function tests ⓘ renal function ⓘ |
| treats |
acute hepatic porphyria attacks
ⓘ
neurovisceral symptoms of acute hepatic porphyria ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Givlaari Description of subject: Givlaari is an RNA interference-based therapy used to treat acute hepatic porphyria by reducing the production of toxic heme intermediates in the liver.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.